Amarin Corporation PLC Successfully Completes All Remaining Clinical Studies for AMR101 NDA

MYSTIC, Conn. and DUBLIN, Ireland, Aug. 1, 2011 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, announced today the successful completion of all remaining studies required for the Company's planned new drug application (NDA) for AMR101 for the treatment of patients with very high triglycerides (=500 mg/dl). Completion of these studies is a key step in the Company's plans to submit an NDA for AMR101 by the end of September.